Skip to main content
SpringerLink
Log in

NICE rejects trastuzumab emtansine as price too high

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. Kadcyla: NICE disappointed by manufacturer's decision. Media Release : 7 Aug 2014. Available from: URL: http://www.nice.org.uk.

  2. White C. NICE confirms advanced breast cancer drug is too expensive for NHS. BMJ : 8 Aug 2014. Available from: URL: http://dx.doi.org/10.1136/bmj.g5078.

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE rejects trastuzumab emtansine as price too high. PharmacoEcon Outcomes News 709, 11 (2014). https://doi.org/10.1007/s40274-014-1471-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1471-1

Search

Navigation